Pluri (PLUR) Other Non-Current Assets (2011 - 2025)
Pluri (PLUR) posted quarterly Other Non-Current Assets of $939000.0 for Q4 2025, up 17.38% year-over-year from $800000.0 in Q4 2024, and up 19.31% quarter-over-quarter from $787000.0 in Q3 2025.
Pluri (PLUR) Other Non-Current Assets (2011 - 2025) Analysis & Trends
Pluri (PLUR) has reported Other Non-Current Assets for 14 consecutive years, with $939000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 17.38% year-over-year to $939000.0; the TTM figure through Dec 2025 stood at $939000.0 (up 17.38% YoY), while the FY2025 annual figure was $27000.0, down 61.43% from the prior year.
- Other Non-Current Assets climbed to $939000.0 in Q4 2025 per PLUR's latest filing, from $787000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.0 million in Q2 2022 and bottomed at $2000.0 in Q1 2023.
- Historically, Other Non-Current Assets has averaged $402650.0 across 5 years, with a median of $442000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 14285.71% — and 2023, when it plunged 99.7%.
- Pluri's Other Non-Current Assets stood at $18000.0 in 2021, then soared by 438.89% to $97000.0 in 2022, then jumped by 564.95% to $645000.0 in 2023, then grew by 24.03% to $800000.0 in 2024, then climbed by 17.38% to $939000.0 in 2025.
- Business Quant data shows PLUR's Other Non-Current Assets at $939000.0 in Q4 2025, $787000.0 in Q3 2025, and $27000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 939,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 939,000.00 |
| Sep 30, 2025 | 787,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 786,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 273,000.00 |
| Dec 31, 2023 | 645,000.00 |
| Sep 30, 2023 | 611,000.00 |
| Jun 30, 2023 | 627,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Dec 31, 2022 | 97,000.00 |
| Sep 30, 2022 | 653,000.00 |
| Jun 30, 2022 | 1.01 Mn |
| Mar 31, 2022 | 669,000.00 |
| Dec 31, 2021 | 18,000.00 |
| Sep 30, 2021 | 6,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Mar 31, 2021 | 9,000.00 |